(Updated with stock market price)
PARIS, July 1 (Reuters) – Valneva said on Monday it has received marketing authorization from the European Commission for IXCHIQ, its single-dose vaccine for the prevention of the disease caused by the chikungunya virus.
The stock rose 5.53% to 3.36 euros at 08:18 GMT, outperforming the SBF120 index, which rose 1.9%.
“Ixchiq is the only approved vaccine against chikungunya in the world, thus providing a response to this unmet medical need,” the French medical laboratory declared in a press release.
Chikungunya virus (CHIKV) is a viral disease transmitted by mosquitoes.
The vaccine was already approved by the Canadian and US drug authorities earlier this year. Two applications are still pending, respectively with the UK Medicines and Healthcare products Agency and the Brazilian health agency Anvisa, with a potential authorisation by the end of 2024.
(Written by Pauline Foret, edited by Blandine Hénault)
What stocks to buy?
Making the best investments requires a detailed knowledge of the markets, their mechanisms, the economy and involves diving into the heart of the strategy of each listed company. The Investir editorial team does it for you and reserves its advice on more than 800 stocks for its subscribers. Benefit from their recommendations for buying, speculative buying, spread buying or selling by subscribing to Investir.
I discover the offers
